Floatz logo

ft500

EGFR Positive Solid Tumor

Fate TherapeuticsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the EGFR Positive Solid Tumor cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fate Therapeutics
Phase 1CCC
Fludarabine
Fate Therapeutics
Phase 1CCC
Epirubicin
Fate Therapeutics
Phase 1CC
Nivolumab
Fate Therapeutics
Phase 1CC
TRASTUZUMAB
Fate Therapeutics
Phase 1CC

View all 10 →

Same molecule, other indications

ft500 is also rated in:

Microsatellite InstabilityDormant
CC
Indicative ·
47 / 100
View asset →
squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →